The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome
Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989) · Science · doi:10.1126/science.2523562 · Cited by 6,875
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,520
Global epidemiology and genotype distribution of the hepatitis C virus infection
Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., & Razavi, H. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.027 · Cited by 1,903
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J.-P., Agarwal, K., Buggisch, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402454 · Cited by 1,705
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bacon, B. R., Gordon, S. C., Lawitz, E., Marcellin, P., Vierling, J. M., Zeuzem, S., Poordad, F., Goodman, Z. D., Sings, H. L., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009482 · Cited by 1,626
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316366 · Cited by 1,307
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A. S., Hinestrosa, F., Thuluvath, P. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306218 · Cited by 1,190
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., Shiffman, M. L., Schiff, E., Ghalib, R., Ryan, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402355 · Cited by 1,130
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.023 · Cited by 1,088
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
Lawitz, E., Sulkowski, M. S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z. M., Corregidor, A., DeJesus, E., Pearlman, B., Rabinovitz, M., Gitlin, N., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61036-9 · Cited by 818
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Zeuzem, S., Dusheiko, G. M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R. H., Illeperuma, A., Svarovskaia, E., Brainard, D. M., Symonds, W. T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316145 · Cited by 795
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Symonds, W. T., Hindes, R. G., & Berrey, M. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208953 · Cited by 764
Nelson, D. R., Cooper, J. N., Lalezari, J. P., Lawitz, E., Pockros, P. J., Gitlin, N., Freilich, B. F., Younes, Z. H., Harlan, W., Ghalib, R., et al. (2015) · Hepatology · doi:10.1002/hep.27726 · Cited by 689
Sarrazin, C., Kieffer, T. L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H., Lin, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.037 · Cited by 616
Self-citationLawitz, E., Poordad, F. F., Pang, P. S., Hyland, R. H., Ding, X., Mo, H., Symonds, W. T., McHutchison, J. G., & Membreno, F. E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62121-2 · Cited by 547
Zeuzem, S., Ghalib, R., Reddy, K. R., Pockros, P. J., Ari, Z. B., Zhao, Y., Brown, D. D., Wan, S., DiNubile, M. J., Nguyen, B.-Y., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0785 · Cited by 516
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Sarrazin, C., & Zeuzem, S. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.055 · Cited by 504
Self-citationRazavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hézode, C., Lázaro, P., et al. (2014) · Journal of Viral Hepatitis · doi:10.1111/jvh.12248 · Cited by 477
Self-citationJacobson, I. M., Dore, G. J., Foster, G. R., Fried, M. W., Radu, M., Rafalsky, V. V., Moroz, L., Craxi, A., Peeters, M., Lenz, O., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60494-3 · Cited by 437
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
Wyles, D. L., Ruane, P. J., Sulkowski, M. S., Dieterich, D., Luetkemeyer, A., Morgan, T. R., Sherman, K. E., Dretler, R., Fishbein, D., Gathe, J. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503153 · Cited by 419
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
Bartenschlager, R., Lohmann, V., & Penin, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3046 · Cited by 402
Reesink, H. W., Zeuzem, S., Weegink, C. J., Forestier, N., van Vliet, A., van de Wetering de Rooij, J., McNair, L., Purdy, S., Kauffman, R., Alam, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.013 · Cited by 401
Manns, M., Marcellin, P., Poordad, F., de Araujo, E. S. A., Buti, M., Horsmans, Y., Janczewska, E., Villamil, F., Scott, J., Peeters, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60538-9 · Cited by 376
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Rong, L., Dahari, H., Ribeiro, R. M., & Perelson, A. S. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000544 · Cited by 355
Kuntzen, T., Timm, J., Berical, A., Lennon, N., Berlin, A. M., Young, S. K., Lee, B., Heckerman, D., Carlson, J., Reyor, L. L., et al. (2008) · Hepatology · doi:10.1002/hep.22549 · Cited by 349
Charlton, M., Gane, E. J., Manns, M. P., Brown, R. S., Curry, M. P., Kwo, P. Y., Fontana, R. J., Gilroy, R. K., Teperman, L. W., Muir, A. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.10.001 · Cited by 347
Manns, M., Pol, S., Jacobson, I. M., Marcellin, P., Gordon, S. C., Peng, C.-Y., Chang, T.-T., Everson, G. T., Heo, J., Gerken, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61059-x · Cited by 342
HIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications
Tang, M. W., & Shafer, R. W. (2012) · Drugs · doi:10.2165/11633630-000000000-00000 · Cited by 326
Susser, S., Welsch, C., Wang, Y., Zettler, M., Domingues, F. S., Karey, U., Hughes, E., Ralston, R., Tong, X., Herrmann, E., et al. (2009) · Hepatology · doi:10.1002/hep.23192 · Cited by 318
Self-citationSarrazin, C., Rouzier, R., Wagner, F., Forestier, N., Larrey, D., Gupta, S. K., Hussain, M., Shah, A., Cutler, D., Zhang, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.041 · Cited by 310
Self-citationIn Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061
Lin, C., Lin, K., Luong, Y.-P., Rao, B. G., Wei, Y.-Y., Brennan, D. L., Fulghum, J. R., Hsiao, H.-M., Ma, S., Maxwell, J. P., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313020200 · Cited by 288
Antiviral strategies in hepatitis C virus infection
Sarrazin, C., Hézode, C., Zeuzem, S., & Pawlotsky, J.-M. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60010-5 · Cited by 283
Self-citationImmune Responses to HCV and Other Hepatitis Viruses
Park, S.-H., & Rehermann, B. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.010 · Cited by 265
Summa, V., Ludmerer, S. W., McCauley, J. A., Fandozzi, C., Burlein, C., Claudio, G., Coleman, P. J., DiMuzio, J. M., Ferrara, M., Di Filippo, M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-12 · Cited by 259
Bartels, D. J., Zhou, Y., Zhang, E. Z., Marcial, M., Byrn, R. A., Pfeiffer, T., Tigges, A. M., Adiwijaya, B. S., Lin, C., Kwong, A. D., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/591141 · Cited by 211
McPhee, F., Sheaffer, A. K., Friborg, J., Hernandez, D., Falk, P., Zhai, G., Levine, S., Chaniewski, S., Yu, F., Barry, D., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01186-12 · Cited by 188
Heim, M. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.005 · Cited by 174
Berger, C., Romero‐Brey, I., Radujković, D., Terreux, R., Zayas, M., Paul, D., Harak, C., Hoppe, S., Gao, M., Pénin, F., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.019 · Cited by 158
Reesink, H. W., Fanning, G. C., Farha, K. A., Weegink, C. J., van Vliet, A., Klooster, G. A. E. V. '., Lenz, O., Aharchi, F., Mariën, K., Remoortere, P. V., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.10.033 · Cited by 155
Bartels, D. J., Sullivan, J. C., Zhang, E. Z., Tigges, A. M., Dorrian, J., Meyer, S. D., Takemoto, D., Dondero, E., Kwong, A. D., Picchio, G., et al. (2012) · Journal of Virology · doi:10.1128/jvi.02294-12 · Cited by 147
Gaudieri, S., Rauch, A., Pfafferott, K. J., Barnes, E. J., Cheng, W., McCaughan, G. W., Shackel, N. A., Jeffrey, G. P., Mollison, L. C., Baker, R. I., et al. (2008) · Hepatology · doi:10.1002/hep.22773 · Cited by 140
Muir, A. J., Poordad, F. F., Lalezari, J. P., Everson, G. T., Dore, G. J., Herring, R., Sheikh, A. M., Kwo, P. Y., Hézode, C., Pockros, P. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.3868 · Cited by 134
Lenz, O., Verbinnen, T., Fevery, B., Tambuyzer, L., Vijgen, L., Peeters, M., Buelens, A., Ceulemans, H., Beumont, M. G., Picchio, G., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.032 · Cited by 132
Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A
DeGoey, D. A., Randolph, J. T., Liu, D., Pratt, J. K., Hutchins, C. W., Donner, P., Krueger, A. C., Matulenko, M. A., Patel, S. V., Motter, C. E., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401398x · Cited by 131
Hézode, C., Hirschfield, G. M., Ghesquière, W., Sievert, W., Rodriguez‐Torres, M., Shafran, S. D., Thuluvath, P. J., Tatum, H. A., Waked, I. A., Esmat, G., et al. (2014) · Gut · doi:10.1136/gutjnl-2014-307498 · Cited by 120
Süsser, S., Vermehren, J., Forestier, N., Welker, M. W., Grigorian, N., Füller, C., Perner, D., Zeuzem, S., & Sarrazin, C. (2011) · Journal of Clinical Virology · doi:10.1016/j.jcv.2011.08.015 · Cited by 118
Self-citationPilot-Matias, T., Tripathi, R. L., Cohen, D. E., Gaultier, I., Dekhtyar, T., Lu, L., Reisch, T., Irvin, M., Hopkins, T., Pithawalla, R. B., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04227-14 · Cited by 117
Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir
McPhee, F., Friborg, J., Levine, S., Chen, C., Falk, P. J., Yu, F., Hernandez, D., Lee, M. S., Chaniewski, S., Sheaffer, A. K., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00308-12 · Cited by 110
Moreno, C., Berg, T., Tanwandee, T., Thongsawat, S., Vlierberghe, H. V., Zeuzem, S., Lenz, O., Peeters, M., Sekar, V. J., & Smedt, G. D. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.033 · Cited by 109
Deterding, K., Grüner, N. H., Buggisch, P., Wiegand, J., Galle, P. R., Spengler, U., Hinrichsen, H. M., Berg, T., Potthoff, A., Malek, N. P., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70059-8 · Cited by 104
Dietz, J., Schelhorn, S.-E., Fitting, D., Mihm, U., Süsser, S., Welker, M., Füller, C., Däumer, M., Teuber, G., Wedemeyer, H. H., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02778-12 · Cited by 103
Self-citationPoordad, F. F., Sievert, W., Mollison, L. C., Bennett, M., Tse, E., Bräu, N., Levin, J. M., Sepe, T. E., Lee, S. S., Angus, P., et al. (2015) · JAMA · doi:10.1001/jama.2015.3860 · Cited by 102
Sarrazin, C., Lathouwers, E., Peeters, M., Daems, B., Buelens, A., Witek, J., Wyckmans, Y., Fevery, B., Verbinnen, T., Ghys, A., et al. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.01.003 · Cited by 102
Self-citationNew Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development
Pawlotsky, J. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1371007 · Cited by 100
Poordad, F. F., Schiff, E. R., Vierling, J. M., Landis, C. S., Fontana, R. J., Yang, R., McPhee, F., Hughes, E., Noviello, S., & Swenson, E. S. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30154-9 · Cited by 99
Krishnan, P., Tripathi, R. L., Schnell, G., Reisch, T., Beyer, J. M., Irvin, M., Xie, W., Larsen, L. M., Cohen, D. E., Podsadecki, T. J., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00998-15 · Cited by 96
Wiese, M., Fischer, J., Löbermann, M., Göbel, U., Grüngreiff, K., Güthoff, W., Kullig, U., Richter, F., Schiefke, I., Tenckhoff, H., et al. (2013) · Hepatology · doi:10.1002/hep.26644 · Cited by 94
Lenz, O., Vijgen, L., Berke, J. M., Cummings, M. D., Fevery, B., Peeters, M., Smedt, G. D., Moreno, C., & Picchio, G. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.028 · Cited by 87
Krishnan, P., Tripathi, R. L., Schnell, G., Reisch, T., Beyer, J. M., Dekhtyar, T., Irvin, M., Xie, W., Larsen, L. M., Podsadecki, T. J., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30071-4 · Cited by 83
Dietz, J., Süsser, S., Berkowski, C., Perner, D., Zeuzem, S., & Sarrazin, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134395 · Cited by 74
Self-citationKwo, P. Y., Gitlin, N., Nahass, R., Bernstein, D. E., Rojter, S. E., Schiff, E., Davis, M. N., Ruane, P. J., Younes, Z. H., Kalmeijer, R., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30168-9 · Cited by 70
Palanisamy, N., Danielsson, A., Kokkula, C., Yin, H., Bondeson, K., Wesslén, L., Duberg, A., & Lennerstrand, J. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.04.018 · Cited by 68
Lawitz, E., Matusow, G., DeJesus, E., Yoshida, E. M., Felizarta, F., Ghalib, R. H., Godofsky, E. W., Herring, R., Poleynard, G. D., Sheikh, A. M., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30158-6 · Cited by 66
Franco, S., Tural, C., Nevot, M., Moltó, J., Rockstroh, J. K., Clotet, B., & Martı́nez, M. Á. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.05.010 · Cited by 61
Dore, G. J., Lawitz, E., Hézode, C., Shafran, S. D., Ramji, A. S., Tatum, H. A., Taliani, G., Tran, A., Brunetto, M. R., Zaltron, S., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.10.007 · Cited by 58
the ANRS AC11 HCV Group, Vallet, S., Viron, F., Henquell, C., Guillou‐Guillemette, H. L., Lagathu, G., Abravanel, F., Trimoulet, P., Soussan, P., Schvoerer, É., et al. (2011) · Antiviral Therapy · doi:10.3851/imp1900 · Cited by 55
Pasquinelli, C., McPhee, F., Eley, T., Villegas, C., Sandy, K., Sheridan, P. L., Persson, A., Huang, S.-P., Hernandez, D., Sheaffer, A. K., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05854-11 · Cited by 51
Götte, M. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.08.004 · Cited by 49
Kwo, P. Y., Gane, E. J., Peng, C., Pearlman, B. L., Vireling, J., Serfaty, L., Buti, M., Shafran, S. D., Stryszak, P., Lin, L.-W., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)31088-6 · Cited by 39
Howe, A., Black, S., Curry, S., Ludmerer, S. W., Liu, R., Barnard, R. J. O., Newhard, W., Hwang, P. M. T., Nickle, D. C., Gilbert, C., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu696 · Cited by 36
Meyer, S. D., Ghys, A., Foster, G. R., Beumont, M. G., van Baelen, B., Lin, T. I., Dierynck, I., Ceulemans, H., & Picchio, G. (2013) · Journal of Viral Hepatitis · doi:10.1111/jvh.12046 · Cited by 19
Howe, J. A., Long, J., Black, S., Chase, R., McMonagle, P., Curry, S., Thompson, S., DiNubile, M. J., & Howe, A. Y. M. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu078 · Cited by 18
Zeuzem, S., Ghalib, R., Reddy, K. R., Pockros, P. J., Ben‐Ari, Z., Zhao, Y., Brown, D. C., DiNubile, M. J., Robertson, M. N., Wahl, J., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30056-8 · Cited by 15
Cited by
EASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Bourlière, M., Gordon, S. C., Flamm, S. L., Cooper, C. L., Ramji, A., Tong, M., Ravendhran, N., Vierling, J. M., Tran, T. T., Pianko, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613512 · Cited by 557
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
Pawlotsky, J.-M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.04.003 · Cited by 519
Protease inhibitor therapy for hepatitis C virus-infection
de Leuw, P., & Stephan, C. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1454428 · Cited by 51
Metadata
- Authors
- Sarrazin, C.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 64
- Issue
- 2
- Pages
- 486-504
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2112024536
- Cited by
- 423
- References
- 76
- FWCI
- 40.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.